ELF3 emerges as a novel prognostic indicator implicated in gastric cancer progression and correlated with unfavorable clinical outcomes

Table 2 Univariate and multivariate analyses of prognostic factors for overall survival of stomach adenocarcinoma patients in the study cohort

Variables	Univariate analysis			Multivariate analysis
	HR	95%CI	P value	HR	95%CI	P value
Age (years)
< 60	Reference
≥ 60	0.901	0.526-1.544	0.704
Gender
Female	Reference
Male	1.166	0.672-2.023	0.585
Tumor size (cm)
< 5	Reference			Reference
≥ 5	2.342	1.355-4.047	0.002	1.351	0.729-2.503	0.339
T stage
T1 + T2	Reference			Reference
T3 + T4	3.427	1.366-8.594	0.009	1.117	0.402-3.100	0.832
N stage
N0 + N1	Reference			Reference
N2 + N3	2.421	1.380-4.248	0.002	0.497	0.106-2.337	0.376
TNM stage
I + II	Reference			Reference
III + IV	2.812	1.588-4.979	< 0.001	3.652	0.750-17.789	0.109
ELF3 expression
Low	Reference			Reference
High	5.148	2.793-9.488	< 0.001	4.154	2.135-8.081	< 0.001
Vascular invasion
No	Reference			Reference
Yes	2.672	1.405-5.081	0.003	2.313	1.196-4.474	0.013
Ki-67
Low	Reference
High	0.759	0.450-1.282	0.303
E-cadherin
Low	Reference
High	0.649	0.384-1.096	0.106

TNM: Tumor-node-metastasis; ELF3: E74-like ETS transcription factor 3; HR: Hazard ratio; CI: Confidence interval.